Skip to content

Regenxbio RGNX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
Biogen logo
BiogenBIIB
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's deferred tax assets and other non-current assets?
Regenxbio (RGNX) reported deferred tax assets and other non-current assets of $5.51M in Q1 2026.
How has Regenxbio's deferred tax assets and other non-current assets changed year-over-year?
Regenxbio's deferred tax assets and other non-current assets increased by 84.6% year-over-year, from $2.99M to $5.51M.
What is the long-term trend for Regenxbio's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Regenxbio's deferred tax assets and other non-current assets has grown at a -2.7% compound annual growth rate (CAGR), from $5.28M to $4.61M.